BR112021022828A2 - Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors - Google Patents

Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors

Info

Publication number
BR112021022828A2
BR112021022828A2 BR112021022828A BR112021022828A BR112021022828A2 BR 112021022828 A2 BR112021022828 A2 BR 112021022828A2 BR 112021022828 A BR112021022828 A BR 112021022828A BR 112021022828 A BR112021022828 A BR 112021022828A BR 112021022828 A2 BR112021022828 A2 BR 112021022828A2
Authority
BR
Brazil
Prior art keywords
egfr
tyrosine kinase
kinase inhibitors
combination therapies
bispecific anti
Prior art date
Application number
BR112021022828A
Other languages
Portuguese (pt)
Inventor
Matthew Lorenzi
Sheri Moores
Sylvie Laquerre
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Publication of BR112021022828A2 publication Critical patent/BR112021022828A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração. a presente invenção refere-se a terapias de combinação com anticorpos biespecíficos anti-egfr/c-met e inibidores de tirosina-quinase egfr da terceira geração.combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors. The present invention relates to combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors.

BR112021022828A 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors BR112021022828A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112021022828A2 true BR112021022828A2 (en) 2022-04-12

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022828A BR112021022828A2 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors

Country Status (12)

Country Link
EP (1) EP3968985A4 (en)
JP (1) JP2022531980A (en)
KR (1) KR20220010731A (en)
CN (1) CN113840601A (en)
AU (1) AU2020275272A1 (en)
BR (1) BR112021022828A2 (en)
CA (1) CA3140360A1 (en)
EA (1) EA202193117A1 (en)
IL (1) IL287962A (en)
MA (1) MA55978A (en)
MX (1) MX2021013955A (en)
SG (1) SG11202112412QA (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AR070861A1 (en) * 2008-03-06 2010-05-12 Genentech Inc USE OF COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS
SG10201800757TA (en) * 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CA3182876A1 (en) * 2012-11-21 2014-05-30 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
AR111469A1 (en) * 2017-04-21 2019-07-17 Yuhan Corp COME OUT OF AN AMINOPIRIDINE DERIVATIVE COMPOUND, A CRYSTAL FORM OF THE SAME, AND A PROCESS TO PREPARE THE SAME

Also Published As

Publication number Publication date
AU2020275272A1 (en) 2021-12-02
MX2021013955A (en) 2022-03-11
MA55978A (en) 2022-03-23
EP3968985A1 (en) 2022-03-23
CN113840601A (en) 2021-12-24
IL287962A (en) 2022-01-01
EA202193117A1 (en) 2022-02-11
SG11202112412QA (en) 2021-12-30
EP3968985A4 (en) 2023-07-26
KR20220010731A (en) 2022-01-26
CA3140360A1 (en) 2020-11-19
JP2022531980A (en) 2022-07-12

Similar Documents

Publication Publication Date Title
JOP20210304A1 (en) Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
CY1124384T1 (en) CONSTRUCTIONS OF DIPLOID ANTIBODIES THAT BIND TO EGFRVIII AND CD3
CL2022002771A1 (en) Affinity matured and humanized antibodies to fcrh5 and their use (cl divisional 201703195).
CR20190434A (en) Anti-lag3 antibodies
BR112017023943A2 (en) cd3-binding heterodimeric antibodies and tumor antigens
EA201890028A1 (en) HUMAN CD3 ANTIBODY
MX358728B (en) Humanized pan-her antibody compositions.
BR112018000475A2 (en) Bispecific antibody constructs that bind to dll3 and cd3
EA201890337A1 (en) ANTIBODY CONSTRUCTIONS TO FLT3 AND CD3
PE20221007A1 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY
CY1122456T1 (en) MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER
BR112016000903A2 (en) antibodies
PH12020550055A1 (en) Antibodies that bind egfr and cmet
CR20160199A (en) COMBINED THERAPY WITH AN ANTI-ANG2 ANTIBODY AND A CD40 AGONIST
JOP20210233A1 (en) Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
EA202092000A1 (en) EGFR DIMERIZATION INHIBITORS AND THEIR USE
CL2020002103A1 (en) Anti-htra1 antibodies and methods of using them. (divisional request 201801139)
EA201791527A1 (en) BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII
CL2018003527A1 (en) Anti-egfr antibody and drug conjugates.
BR112019001206A2 (en) humanized monoclonal antibodies targeting ve-ptp (hptp-ss)
AR094403A1 (en) ANTI-HER3 ANTIBODY COMBINATION THERAPY
CL2020002540A1 (en) Anti-hla-g antibodies and their use
EA201990894A9 (en) ANTI-PD-1 / ANTI-HER2 HETERODIMERIC BASPECIFIC ANTIBODY WITH NATURAL ANTIBODY STRUCTURE AND METHOD FOR ITS PRODUCTION
PE20230381A1 (en) RGMA BINDING PROTEIN
SG10201801219VA (en) Anti-HER2 Antibodies